Blumberg EA, Hauser IA, Stanisic S, Mueller E, Berenson K, Gahlemann CG, Humar A, Jardine AG. Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States. Transplantation; 2010; 90,(12):1420-1426

Tony H, Burmester G, Schulze-Koops H, Grünke M, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier F, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog A, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T and GRAID investigators. Cross-Sectional Analysis of the Efficacy of Rituximab in 384 Patients with Different Autoimmune Diseases: German Registry of Autoimmune Diseases (GRAID). 2010. Presented at the EULAR Annual European Congress of Rheumatology; Rome, Italy, June 16-19, 2010, SAT 0191. [Poster Presentation]

Tony H, Burmester G, Schulze-Koops H, Grünke M, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier F, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog A, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T and GRAID investigators. Safety Data of Patients with Different Autoimmune Diseases Treated with Rituximab: German Registry of Autoimmune Diseases (GRAID). 2010. Presented at the EULAR Annual European Congress of Rheumatology; Rome, Italy, June 16-19, 2010, SAT 0190. [Poster Presentation]

Rains BM, Katz LM, Stern LS, Wiederkehr DP, Arikian SR. The use of intranasal amphotericin B in chronic rhinosinusitis patients: A U.S. retrospective chart review. American College of Allergy, Asthma & Immunology 2005 Annual Meeting; 2005 November 4-9; Anaheim, California; 2005.

Berenson K, Casciano R, Makenbaeva D, Mozaffari E, Lamerato L, Corbelli J. Economic Consequences of Severe Bleeding in Patients with Acute Coronary Syndrome in the USA. Advances in Therapy. 2010 July 29, 2010;27(8):564-79.
Berenson K, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Lamerato L, et al. Economic consequences of ACS-related rehospitalizations in the US. Curr Med Res Opin. 2010 Feb;26(2):329-36.

Mueller E, Seifert C, Gultyaev D, Hessel F, Wasem J. Methodische Herausforderungen einer Budget Impact Analyse von Medikamenten zur Behandlung von Patienten mit Vorhof-flimmern. Presented at the Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Annual Meeting; Berlin, Germany, March 1-2, 2010. [Oral Presentation]

Pineo G, Lin J, Stern L, Subrahmanian T. Robust Univariate And Multivariate Sensitivity Analysis Confirm That Enoxaparin Is Cost-Saving To The Payers Compared With UFH For VTE Prevention In Patients With Ischemic Stroke: Analysis Of The PREVAIL Data. Foothills Hospital, University of Calgary, Calgary, Alberta, Canada sanofi-aventis U.S., Bridgewater, NJ, USA Analytica International, New York, NY, USA; 2010. p. 2.

Nixon R, Mueller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract. 2009; 63(5):766–775.
Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Antoñanzas Villar F, Greiner W, Jönsson B. Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe—The HEALTH Model. Value in Health. 2009. Published Online: Mar 11 2009.

Wiederkehr D, Berenson K, Casciano R, Stern L, Makenbaeva D, Mozaffari E, et al. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. Curr Med Res Opin. 2009 Sep;25(9):2317-25.

Wiederkehr D, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Corbelli J. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin. 2009 Sep;25(9):2327-34.

Schwander B, Haller H. Eprosartan – Gesundheitsökonomische Betrachtung; Antihypertensive Schlaganfallprophylaxe und gesundheitsökonomische Aspekte. In: German Society for Internal Medicine; 113th Annual Meeting , Wiesbaden, Germany, April 14 – 18, 2007.

Schwander B, Lindgren P, Gradl B. The cost-effectiveness (cost-utility) of eprosartan in hypertensive patients with cerebrovascular disease in Belgium, Germany, Spain, UK, and Sweden. In: ISPOR 10th European Congress, Dublin, Ireland, October 22, 2007.

Lindgren P, Schwander B, Zöllner Y, Jönsson B. cost-utility analysis of Eprosartan compared to Enalapril and Ramipril in the treatment of moderate to severe hypertension in Sweden. In: ISPOR 9th European Congress, Copenhagen, Danmark, October 28 – 31, 2006.

Rosery H, Reimbursement of Ventricular Assist Devices in Europe – A Road Map for the Approval Process. In: 14th Congress of the ISRBP meeting, Leuven, Belgium, August 31 – September 2, 2006.

Williams SA, Stern LS, McMurray JJ, Dunlap ME, Michelson EL, Doyle JJ, et al. A pharmacoeconomic evaluation of the effects of candesartan on cardiovascular hospitalizations in patients with chronic heart failure. The 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; 2006 May 7-9; Washington, DC; 2006.

Hering D, Piper C, Bergemann R, Hillenbach C, Dahm M, Huth C, Horstkotte D. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest. 2005 Jan;127(1):53-9.

Hering D, Piper C, Bergemann R, Hillenbach C, Horstkotte D. Influence of two different reporting systems on counts of thromboembolic and bleeding complications after St. Jude medical valve replacement: results from the GELIA study. J Heart Valve Dis. 2005 Jul;14(4):467-71; discussion 472-5.

Janka HU, Hessel F, Mueller E. Economic analysis of the treatment with insulin glargine plus oral antidiabetics (BOT) compared to twice daily premixed insulin (CT) based on the LAPTOP trial. In: ISPOR 10th European Congress, Dublin, Ireland, October 20 – 23, 2007.

Janka HU, Hessel F, Walzer S, Müller E. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes – a simulation with the Diabetes Mellitus Model (DMM). International Journal of Clinical Pharmacology and Therapeutics. 2007; 45(12):623-630.

Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount. Hood Challenge Meeting. Diabetes Care. 2007;30(6):1638-46.

Mueller E, Huppertz E, Stridde E. Comparing British and German diabetes guidance with respect to longterm outcomes and associated costs: Results from the EAGLE diabetes simulation model. In: ISPOR 10th European Congress, Dublin, Ireland, October 22, 2007.
Mueller E, Huppertz E, Stridde E. Vergleich der deutschen und britischen Diabetes Leitlinien: Auftreten von Spätkomplikationen und daraus resultierende Kosten - Simulationen mit dem EAGLE-Modell. In: German Diabetes Society, 42nd Annual Meeting, Hamburg, Germany, May 16 – 19, 2007.

Stridde E, Bierwirth R, Huppertz E,. Mueller E. Entwicklung mikrovaskulärer Langzeitkomplikationen und der assoziierten Kosten bei Patienten mit Typ-2-Diabetes in der diabetologischen Schwerpunktpraxis: Ergebnisse einer 10-Jahres-Simulation der TEMPO®-Patientenkohorte mit dem EAGLE-Diabetes-Modell unter Einbeziehung der KoDiM-Daten. In: German Diabetes Society, 42nd Annual Meeting, Hamburg, Germany, May 16 – 19, 2007.

Bergemann R, Hauner H, Morris AD, Dinneen SF, Suissa SF, Gultyaev D, Maxion-Bergemann S, Müller E. Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mellitus Model (DMM). Journal of Medical Economics 2006; 9: 83-99.

Brennan A, Ara R, Sterz R, Matiba B, Bergemann R. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ. 2006 Dec;7(4):276-84.

Maxion-Bergemann S, Walleser S, Müller E et al. Diabetes Mellitus Model (DMM): Internal Validation of a Computer-Simulation Model for Type 1 and Type 2 Diabetes. Journal of Medical Economics 2006; 9: 69-82.

Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, Bolinder B, Gerber R, Kvasz M, Bergemann R. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther. 2006 Apr;8(2):219-36.

Mueller E, Walzer S, Pieper L, Klotsche J, Stridde E. Comparing the development of a german diabetes population with respect to long-term outcomes using data from the DETECT Study and the EAGLE diabetes simulation model. In: ISPOR 9th European Congress, Copenhagen, Danmark, October 28 – 31, 2006.

Mueller E., Walzer S, Huppertz E, Stridde E. Vergleich der deutschen und britischen Diabetes Leitlinien im Hinblick auf die Entwicklung von Spätkomplikationen: Simulationen mit dem EAGLE-Modell. [Comparison of the German and British diabetes guidelines in terms of late diabetic complications: Simulations with the EAGLE model.] In: German Diabetes Society, 41st Annual Meeting, Leipzig, Germany, May 24 – 27, 2006.

Rosery H, Bergemann R, Marx SE, Boehnke A, Melnick J, Sterz R, Williams L. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig. 2006;26(11):629-38.

Walzer S , Huppertz E, Mueller E, Janka HU. Better HbA1c control with bot versus CT avouds long-term micro-vascular complications in patients with Tyoe-2-Diabetes: Model simulations with the DMM. In: ISPOR 9th European Congress, Copenhagen, Danmark, October 28 – 31, 2006.

Walzer S, Bergemann R, Freemantle N, Mathieu C, Kvasz M, Marchant N, Mueller E. External Validation of the Economic Assessment of Glycemic Control and Long-term Effects of Diabetes (EAGLE) Model. In: 42nd EASD Meeting, Copenhagen-Malmoe, Sep 14-17, 2006.

Bergenstal RM, Gerber RA, Bolinder B, Stern L, Katz LM, Wang L. Cost of diabetes treatment in patients with type 1 or 2 diabetes with or without complications in the United States. Diabetes. 2005;54(Suppl 1):A612.

Bergenstal RM, Gerber RA, Bolinder B, Stern L, Katz LM, Wang L. Direct costs of treatment for patients with Type 1 or Type 2 diabetes with or without complications in the USA. European Association for the Study of Diabetes; 2005 September; Athens, Greece; 2005.

Casciano RN, Walzer S, Müller E. Krankheitsmodell am Beispiel Diabetes - das EAGLE-Modell. Gesundheitsökonomie & Qualitätsmanagement, 2005, Supplement 2, 10: S64-S69.

Kvasz M, Walzer S, Maxion-Bergemann S, Bergemann R, Casciano R. Validation of the economic assessment of glycemic control and long-term effects (EAGLE) diabetes model. 2005 October 21-24 San Francisco; 2005.

"Maxion-Bergemann S, Huppertz E, Jacobs LD, Müller E, Walleser S. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the ""diabetes mellitus model"". Int J Clin Pharmacol Ther. 2005 Jun;43(6):271-81."

Mueller E, Stridde E, Clemens A Huppertz E, Bierwirth R: Entwicklung mikrovaskulärer Langzeitkomplikationen bei Patienten mit Typ-2-Diabetes in der diabetologischen Schwerpunktpraxis: Ergebnisse einer 10-Jahres-Simulation der TEMPO-Patientenkohorte mit dem EAGLE-Diabetes-Modell. In: German Diabetes Society, 40th Annual Meeting, Berlin, Germany, May 4-7, 2005.

Walzer S, Maxion-Bergemann S, Bergemann R, Casciano R, Mueller E: Internal Validation of the Economic Assessment of Glycemic Control and Long-term Effects (EAGLE) Diabetes Model. In: ISPOR 8th European Congress, Florence, Italy, Nov. 6-9, 2005.

Walzer S, Maxion-BergemannS, Bergemann R, Casciano R, Mueller E: Validation of the Economic Assessment of Glycemic Control and Long-term Effects (EAGLE) Diabetes Model. In: Society for Medical Decision Making, Annual Meeting, San Francisco, USA, Oct 19-22, 2005.

Weichman K, Ren C, Kurian M, Heekoung AY, Casciano R, Stern L, et al. The effectiveness of adjustable gastric banding: a retrospective 6-year U.S. follow-up study. Surg Endosc. 2010 Jun 24.

Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24(1):21-37.
"Shaheen NJ, Berenson KL, Doyle JJ, Brown KA. How Do Consumers Take ""Over-the-Counter"" Omeprazole? Digestive Disease Week; 2006 May 2006; Los Angeles, CA; 2006."

Mueller E; Schwander B; Zerwes U; Bergemann R. Klinische und ökonomische Evaluation des diagnostischen Verfahrens ‚Kapselendoskopie' zur Untersuchung des Dünndarms. DIMDI DAHTA-Datenbank; Dokument-Nr. DAHTA107, Berichts-Nr. ANALYTICA002. http://gripsdb.dimdi.de/de/hta/hta_berichte/hta107_bericht_de.pdf

Brixner DI, Horowicz-Mehler N, Stern LS, Doyle JJ, Dolgitser M, Hagan M. Contraceptive and Non-Contraceptive Benefits of the Levonorgestrel Intrauterine System (LNG-IUS) in a Vertically Integrated HMO (Henry Ford Health System). The 2007 International Society for Pharmacoeconomics and Outcomes Research 2007 May 19-23, 2007; Arlington, VA 2007.

Kaunitz AM, Stern LS, Doyle JJ, Etschmaier MR. Use of Levonorgestrel - IUD in the treatment of Menorrhagia: Improving patient outcomes while reducing the need for surgical management. Managed Care Interface. 2007;20(3):47-50.

"Rosery H. ""Hochfokussierter Ultraschall"" ( MRgFUS) - eine neue Therapieoption? Symposium. Charite - Universitätsmedizin Berlin. Klinik für Strahlenheilkunde. March 2005"

Rosery H; Thielecke F; Thieme M. Magnetic Resonance Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids. DIMDI DAHTA-Datenbank; Dokument-Nr. DAHTA80, Berichts-Nr. ANALYTICA001. http://gripsdb.dimdi.de/de/hta/hta_berichte/hta080_anhang_en.pdf http://gripsdb.dimdi.de/de/hta/hta_berichte/hta080_bericht_en.pdf

Chalfin DB, Trzeciak S, Likourezos A, Baumann BM, Dellinger P. Impact of delayed transfer of critically ill patients from the emergency department to the intensive care unit. Critical Care Medicine. 2007;35(6).

Mueller E, Walzer S, Krone FA,. Fassbinder W. Kosteneinsparung in der Behandlung der renalen Anämie durch subkutane Applikation von Epoetin beta [Cost savings in the treatment of renal anemia due to subcutaneous application of epoetin beta]. Nieren- und Hochdruckkrankheiten 2008;37(8):404-411.

Shorr AF, Mannino DM, Doyle JJ, Stern LS, Dolgitser M, Siegartel LR, et al. The GOLD staging system: Implications for healthcare utilization. American Thoracic Society; 2006 May San Diego, California; 2006.

Shorr AF, Stern LS, Raut MK, Rosenblatt LC, Mody S, Hendlish SK, et al. Anemia and Transfusions Among Critically III Patients on Prolonged Mechanical Ventilation The American College of Chest Physicians Annual Meeting; 2006 October 21-26, 2006 Salt Lake City, UT 2006.

Shorr AF, Stern LS, Raut MK, Rosenblatt LC, Mody S, Hendlish SK, et al. Anemia, Transfusions, and Outcomes Among Critically III Patients on Prolonged Mechanical Ventilation The American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition 2006, the 41st International Scientific Assembly of ASHP 2006 December 3-7, 2006 Anaheim, California 2006.

Chaves PHM, Mody SH, Blasi M, Siegartel LR, Stern LS, Doyle JJ, et al. Healthcare costs and resource utilization associated with chronic anemia in older adults; 2005.

Casciano R, Doyle JJ, Kellner J, Dolgitser M, Stern LS, Krukas M, et al. Pharmacoeconomic Evaluation of Heard Immunity Conferred by Seven-Valent Pneumococcal Conjugate Vaccine (Prevnar) in Canada Based on Calgary Region Epidemiological Data The 2007 International Society for Pharmacoeconomics and Outcomes Research 2007 May 19-23, 2007; Arlington, VA 2007.

Janisch H, Möller B, Priebe P, Rössle M, Pape S, Mauss S, et al. Peginterferon alfa-2a (40KD) plus ribavirin versus pegylated interferon alfa-2b (12KD) plus ribavirin. 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2005 November 11-15; San Francisco; 2005.

Janisch HD, Möller B, Priebe P, Rössle M, Pape S, Mauss S, Hartmann P, Freivogel K, Hüppe D: Peginterferon alfa-2a (40KD) plus Ribavirin versus Pegylated interferon alfa-2b (12KD) plus Ribavirin: Ready-to-use syringe (SYR) versus Injector (INJ) (SPRINT). In: 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, Nov 11-15, 2005.

Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ. 2005 Sep;6(3):244-52.

Weiland O, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Foster GR: Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and genotype 2 or 3 infection: individual estimated probability of sustained virological response (SVR). In: EASL, 40th Annual Meeting of the European Association for the Study of the Liver, Paris, April 13-17, 2005.

Garver D, Lazarus A, Rajagopalan K, Katz LM, L.S. S, Dolgitser M, et al. Switching and concomitant prescriptions in bipolar patients: Relationship to race. Psychiatric Services. 2006.

Stern LS, Wiederkehr DW, Doyle JJ, Katz LM, Rajagopalan K. Association between atypical antipsychotic compliance and hopiltalization and emergency department visits in patients with bipolar disorder. The American Psychiatric Association's 159th Annual Meeting; 2006 May 20-25 Toronto, Ontario, Canada; 2006.

Garver D, Lazarus A, Rajagopalan K, Katz LM, Stern LS, Dolgitser M, et al. Psychotropic polypharmacy and racial disparities in patients with bipolar disorder. American Public Health Association; 2005 November; New Orleans, Louisiana; 2005.

Montgomery S, Doyle JJ, Stern L, McBurney CR. Economic considerations in the prescribing of third-generation antidepressants. Pharmacoeconomics. 2005;23(5):477-91.

Mueller E. Key Issues and Principles of Pricing and Reimbursement for Medical Devices. In: The advanced, legal, regulatory and commercial guide to medical devices, C5 conference, Munich, Germany. February 26th - 27th, 2007.

Shorr AF, Stern LS, Raut MK, Rosenblatt LC, Chalfin DB, Hendlish SK, et al. Outcomes of Transfusions in Critically Ill Patients on Prolonged Mechanical Ventilation The Society of Critical Care Medicine 36th Critical Care Congress; 2007 February 17-21; Orlando, Florida; 2007.

Stern LS, Dolgitser M. Use of Medication Coverage Methodology in Measurement of Patient Compliance with Pharmacotherapy. ACCP; 2007; 2007.

Rosery H, Bergemann R. Reimbursement of drugs in Germany - A Road Map for the Approval Process. In: ISPOR 9th European Congress, Podium Presentation, Copenhagen, Danmark, October 28 – 31, 2006.

Stern LS, Doyle JJ, Siegartel LR, Katz LM, Dolgitser M. Use of medication coverage methodology in measurement of patient compliance with pharmacotherapy. ISPOR; 2006 May Philadelphia, Pennsylvania; 2006.

Walzer S, Morlotti L, Mueller E. Comparison of two Budget Impact Modelling approaches: Impact of a new pharmaceutical product on annual health care expenditures and the impact on expenditures and insurance premiums. In: European Society for Medical Decision Making, 10th Biennial European Meeting, Birmingham, UK, June 11-13, 2006.

Chalfin DB, Danis M, Rapoport J, Levy MM, Katz LM, Siegartel LR, et al. Recursive Partitioning and Amalgamation (RECPAM) to predict ICU survival and length of stay. Annual Congress of the Society of Critical Care Medicine; 2005 January; Phoenix, Arizona; 2005.

Danis M, Chalfin DB, Doyle JJ, Bergemann R, Katz LM, Siegartel LR, et al. Development of model-based computer software for ICU resource allocation. Annual Congress of the Society of Critical Care Medicine; 2005 January; Phoenix, Arizona; 2005.

Katz LM, Doyle JJ, Bergemann R, Siegartel LR, Stern L, Chalfin D, et al. Use of a modified recursive partitioning and amalgamation (RECPAM) technique in outcomes research. ISPOR 8th Annual European Congress; 2005 November 6; Florence, Italy; 2005.

Doyle JJ, Stern LS, Dolgitser M, Katz LM, Omar MA, Kahler KH. Treatment patterns and resource utilization in patients with Paget's disease treated with risedronate. ISPOR; 2006 May 20-24; Philadelphia, Pennsylvania; 2006.

Omar MA, Doyle JJ, Stern LS, Katz LM, Wang L, Kahler KH. Budget impact of introducing zoledronic acid to the formulary of a managed care organization for the treatment of Paget's disease of the bone. The Paget Foundation; 2006 January Fort Lauderdale, Florida; 2006.

Omar MA, Stern LS, Katz LM, Doyle JJ, Dolgitser M, Kahler KH. Extended use of bisphosphonates in Paget's disease patients. The Paget Foundation; 2006 January Fort Lauderdale, Florida; 2006.

Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics. 2005;23(3):243-57.

Schmidt E, Kielhorn A: Patient Compliance in the Treatment of Rheumatoid Arthritis with Biologic DMARDS, and Predicting Factors: a Literature Review. In: ISPOR 8th European Congress, Nov. 6-9, 2005.

Duensing L, Eksterowicz N, Macario A, Brown M, Stern L, Ogbonnaya A. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. Curr Med Res Opin 2010;26:1579-85. Published online 30th April 2010.

Berenson K, Chouaid C, Vergnenegre A, Sherman S, Walzer S. First-line Bevacizumab-based Therapy Versus Pemetrexed+Cisplatin for the Treatment of Advanced Adenocarcinoma Non-Squamous Non-Small Cell Lung Cancer: Indirect Comparison Applying Real-life Outcomes. Presented at the ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010. [Poster Presentation].

Casciano R, Bischoff H, Nuijten M, Malangone E, Ray J. Maintenance Erlotinib Versus Pemetrexed for the Treatment of Non-Small Cell Lung Cancer: Indirect Comparison Applying Real-life Outcomes. Presented at the ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010. [Poster Presentation].

Casciano R, Chulikavit M, Di Lorenzo G, Stern L, Liu Z, Wang X, Garay C, Garrison L. Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Advanced Renal Cell Carcinoma after Failure on Treatment with Sunitinib. Presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010. [Abstract Publication].

Casciano R, Chulikavit M, Liu Z, Rogerio J. Estimated Impact of Everolimus of Annual Drug Expenditure in the Treatment of Advanced Renal Cell Carcinoma in a US Health Plan. Presented at the 2010 ISPOR Annual Conference, May 17th-19th, 2010 [Poster Presentation].

Casciano R, Malangone E, Sherman S, Baladi J, Kay A, Kim D, Garay C, Hollaender N, Wang X. An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients. Presented at the American Society of Clinical Oncology 2010 Annual Meeting, Chicago, IL, June 4-8 2010.

Di Lorenzo G, Casciano R, Malangone E, Buonerba C, Sherman S, Wang X, Liu Z, De Placido S. An Adjusted Indirect Comparison of Everolimus and Sorafenib Therapy in Sunitinib-Refractory mRCC Patients Using a Robust Matching Technique. Presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010. [Poster Presentation].

El Ouagari K, Chulikavit M. Cost-effectiveness of treating metastatic renal cell carcinoma (mRCC) patients whose disease failed on VEGF-TKI therapies with everolimus compared to treating with best supportive care (BSC) alone: Canadian societal perspective. Presented at the 2010 ESMO Conference, September 9, 2010 [Poster Presentation].

Korhonen P, Malangone E, Sherman S, Casciano R, Motzer R, Baladi J.F, Haas T, Zuber E, Hollaender N, Kay A, Lebwohl D. Overall survival (OS) of mRCC patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure Time (RPSFT) models: Two analyses from the RECORD-1 trial. Presented at the American Society of Clinical Oncology 2010 Annual Meeting, Chicago, IL, June 4-8 2010.

Chulikavit M, Casciano R, Stern L, Liu Z, Rogerio J. The Cost of Treating Patients with Advanced Renal Cell Carcinoma with Everolimus versus Temsirolimus After Failure on Sunitinib or Sorafenib. Presented at the 2010 ASCO-GU Conference, March 7, 2010 [Poster Presentation].

Malangone E, Casciano R, Sherman S, Berenson K, Stern L, Di Lorenzo G. A Novel Approach to Matching Adjusted Indirect Comparison Analysis Using Common SAS 9.2 Procedures. Presented at the ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010. [Poster Presentation].

Mueller E, Nuijten M, Ravera S, Stanisic S, Walzer S. Societal Cost Savings with Bevacizumab-Based Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients in Italy. ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 6-9, 2010, PCN108. [Poster Presentation]

Mueller E. Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Editorial Lung Cancer Supplement [Submitted for publication].
Mueller E. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer. 2010 Aug;69 Suppl 1:S1-3.2010 Aug;69 Suppl 1:S24-30.

Schmidt E, Bischoff H, Heigener D, Stanisic S, Walzer S. Cost Savings Associated with Bevacizumab-Based Therapy in Patients in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Germany. ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 6-9, 2010, PCN105. [Poster Presentation]

Schmidt E, Stanisic S, Neumann M, Walzer S. Indirect Cost in Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review. ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 6-9, 2010, PCN106. [Poster Presentation]

Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, Chouaid C, Walzer S, Mueller E, Schmidt E. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer Supplement [Submitted for publication].

Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, de Castro Carpeño J,Chouaid C, Walzer S, Mueller E, Schmidt E. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer. 2010 Aug;69 Suppl 1:S24-30.

Stanisic S, de Castro Carpeño J, Walzer S. First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) with Bevacizumab and Societal Cost Savings in Spain. ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 6-9, 2010, PCN107. [Poster Presentation]

Stanisic S, Vergnenègre A, Chouaid C, Müller E, Walzer S. Societal Cost Savings in Metastatic Non-Small Cell Lung Cancer in France. ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 6-9, 2010, PCN104. [Poster Presentation]

Stern L, Arora S, Willet J, Wang X, Liu Z, Yao JC. A Systematic Review of Epidemiology, Treatment Pattern, Economic and Humanistic Studies in Advanced Neuroendocrine Tumors. Presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010. [Abstract Publication].

Weber MM, Lister J, Reichelt C, Pulgar S, Arora S, Berenson K, A Cost-Consequence Model for Octreotide LAR as Treatment for Metastatic Midgut NET. Presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010. [Poster Presentation].

Willet J, Stern L, Arora S, Wang X, Liu Z, Beaumont JL. Advanced Neuroendocrine Tumors: A Structured Review of the Quality of Life Literature. Presented at the 35th ESMO Congress, Milan, Italy, October 8-12, 2010.[Abstract Publication].

Wiederkehr D, Kaura S, Ogbonnaya A, Stern L. Cost associated with distant, contralateral and locoregional breast cancer recurrence in a vertically integrated health system. 44th American Society of Clinical Oncology Annual Meeting; 2008; Chicago, Illinois USA; 2008.

Doyle JJ, Neugut AI, Jacobson JS, Wang J, McBride R, Grann A, et al. Radiation Therapy, Cardiac Risk Factors, and Cardiac Toxicity in Early-Stage Breast Cancer Patients. Int J Radiation Oncology Biol Phys. 2007;68(1):82-93.

Doyle JJ, Hershman DL, Neugut AI, Stern LS, Katz LM, Dolgitser M. Chemotherapy-related adverse events among breast cancer patients: A retrospective analysis of the SEER-Medicare database. American Society of Clinical Oncology; 2006 June Atlanta, Georgia; 2006.

Geary U, Lewis G, Erny S, Gyldmark M, Morlotti L, Walzer S. A sensitivity analysis of the cost per Quality Adjusted Life Year (QALY) of trastuzumab in the treatment of Early Breast Cancer (EBC). In: ISPOR 9th European Congress, Copenhagen, Danmark, October 28 – 31, 2006.

Katz LM, Howell J, Doyle JJ, Stern LS, Rosenblatt LC, Piech CT, et al. Outcomes and charges of elderly patients with acute myeloid leukemia. American Journal of Hematology. 2006;81(11):850-7.

Lewis G, Morlotti L, Creeden J, Gyldmark M, Peake MD. Cost-effectiveness of Erlotinib compared with Docetaxel for the treatment of relapsed Non-Small Cell Lung Cancer (NSCLC) in the UK . In: ISPOR 9th European Congress, Copenhagen, Danmark, October 28 – 31, 2006.

Walzer S, Memran M, Morlotti L. Modeling and Estimating Preferences Over Treatments for Breast Cancer: Applied conjoint analysis with physicians in Europe and United States. In: ISPOR 11th Annual International Meeting; Philadelphia, USA, May 20 – 24, 2006.

Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study Journal of Clinical Oncology 2005;23(34):8597-605.

Santos C, Stern L, Katz L, Watson T, Gause B. Biovaxid vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of a Phase II trial and status of a controlled, randomized Phase III trial. Annual Meeting of the American Society of Hematology; 2005 December; Atlanta, Georgia; 2005.

Berenson K, Arora S, Kymes S, Hollander D, Fiscella R, Burke C, Patel V. Cost Benefit Analysis of Bimatoprost Compared to Other Prostaglandin Analogues, In Patients with Primary Open Angle Glaucoma (POAG) in the United States: A Payer's Perspective. Presented at the Academy of Managed Care Pharmacy 22nd Annual Meeting, April 7-10, 2010. [Poster Presentation].

Berenson K, Kymes S, Walt J, Siegartel L. The Relationship of Mean Deviation Scores and Resource Utilization Among Patients with Glaucoma. Glaucoma Journal. 2009 June - July 2009;18(5):390 - 4.

Pasquale LR, Walt JG, Stern LS, Wiederkehr D, Malangone E, Dolgitser M. Healthcare Charges in Patients with Glaucoma who Undergo Laser Trabeculoplasty. Advances In Therapy. 2009 November 17, 2009. 26(12):85-7.

Tsai J, Lee J, Williams K, Walt JG, Doyle JJ, Stern LS, et al. The Impact of Pharmacotherapy Compliance on Healthcare Charges in Patients with Primary Open-Angle Glaucoma. The 2007 International Society for Pharmacoeconomics and Outcomes Research; 2007 May 19-23, 2007; Arlington, VA 2007.

Walt JG, Chiang TH, Doyle JJ, Berenson KL. Cost of Standard Care Treatment in Patients with Progression of Primary Open Angle Glaucoma. 2007 International Society for Pharmacoeconomics and Outcomes Research 2007 May 19-23, 2007; Arlington, VA; 2007.

Walt JG, Chiang TH, Stern LS, Doyle JJ. Characterization of the Living Environments of End-Stage Glaucoma Patients and Use of Low-Vision Care Services: A Physician Survey Study. Visual Impairment Research. 2007;9(1):23-31.

Walt JG, Chiang TH, Stern LS, Doyle JJ. End-Stage Glaucoma Low Vision Care Services. Visual Impairment Research. 2007.

Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, et al. Utility assessment to measure the impact of dry eye disease. Ocular Surface. 2006;4(3):155-61.

Lee P, Levin L, Walt J, Chiang T, Stern L, Doyle J, et al. Characteristics Associated with Increased Healthcare Charges of Patients with Primary Open-Angle Glaucoma (POAG). American Academy of Ophthalmology; 2006 November 2006; Las Vegas, NV; 2006.

Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006 Jan;124(1):12-9.

Lee PP, Walt JW, Doyle JJ, Stern LS, Katz LM, Siegartel LR. Association between IOP fluctuation and glaucoma progression. American Glaucoma Society; 2006 March Charleston, South Carolina; 2006.

Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006 Jan;141(1):24-30.

Pasquale LR, Walt JG, Chiang TH, Katz LM, Stern LS, Doyle JJ, et al. Healthcare charges of patients with ocular hypertension. American Glaucoma Society; 2006 March Charleston, South Carolina; 2006.

Traverso C, Walt J, Chiang T, Stern L, Doyle J, Hendlish S, et al. Effect of Intra-Ocular Pressure (IOP) Lowering Medication on Risk of Ocular Ischemic Events: A Case-Control Analysis. American Academy of Ophthalmology; 2006 November 2006; Las Vegas, NV; 2006.

Tsai J, Walt JG, Doyle JJ, Stern LS, Katz LM, Siegartel LR, et al. Pharmacotherapy compliance and glaucoma surgery in patients with primary open-angle glaucoma. American Glaucoma Society; 2006 March Charleston, South Carolina; 2006.

Walt JG, Chiang T, Wang L, Stern LS, Siegartel LR, Doyle JJ, et al. The relationship of mean deviation scores and resource utilization among patients with glaucoma: A retrospective US chart review analysis. Association of Research Vision Ophthamology Annual Meeting (ARVO); 2006 April 30-May 4 Fort Lauderdale, Florida; 2006.

Wentzloff J, Walt JG, Chiang TH, Katz LM, Stern LS, Doyle JJ, et al. Healthcare charges of patients with primary open-angle glaucoma. Association for Research in Vision and Ophthamology (ARVO); 2006 April 30-May 4; Fort Lauderdale, Florida; 2006.

Buchholz P, Steeds C, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, et al. Utility assessment among patients with dry eye disease in the UK. ISPOR 8th Annual European Congress; 2005 November 8; Florence, Italy; 2005.

Gieser DK, Williams RT, O'Connell W, Dul M, Pasquale LR, Walt JG, et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: A U.S. multi-site retrospective study. International Congress Series. 2005;1282C:387-92.

Gieser DK, Williams RT, O'Connell W, Dul M, Walt JG, Buchholz PM, et al. Resource utilization of end-stage glaucoma patients receiving low vision care: A US multi-site retrospective study. Vision 2005; 2005 April; London, England; 2005.

Gieser DK, Williams RT, O'Connell W, Dul M, Walt JG, Buchholz PM, et al. Resource utilization of end-stage glaucoma patients receiving low vision care: A US multi-site retrospective study. International Congress Series. 2005;1282(In press).

Gieser DK, Williams RT, O'Connell W, Pasquale L, Walt JG, Siegartel LR, et al. Resource utilization of end-stage glaucoma patients receiving visual rehabilitation care: A U.S. multisite retrospective study. American Academy of Ophthalmology 2005 Annual Meeting; 2005 October 17-18; Chicago, Illinois; 2005.

Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005 Oct;89(10):1245-9.

Walt JG, Buchholz PM, Chiang TH, Stern LS, Doyle JJ. Characterization of end-stage glaucoma patients and use of low vision care services: A survey study. Vision 2005; 2005; London, England; 2005.

Shorr AF, Doyle JJ, Stern LS, Dolgitser M, Zilberberg MD. Anemia in chronic abstructive pulmonary disease; epidemiology and economic implications. Current Medical Research And Opinion. 2008;24(4):1123-30.

Bukstein DA, Murphy KR, Katz LM, Ramachandran S, Doyle JJ, Stern LS. Outcomes Among a Young Population of Pediatric Asthma patients Using Controller Therapies: Results from a Retrospective Database Analysis. Pediatric Asthma, Allergy & Immunology. 2007;20(4):211-21.

Hitchcock W, Mellon M, Memran M, Parasuraman B, Ramachandran S, Walzer S. Caregiver Preferences for Pediatric Asthma Treatment Delivery Systems. Advances in Therapy. 2007 November/December 2007;24(6):1240 - 53.

Berman JM, Lumry WR, Stern LS, Katz LM, Wang L, Rosenblatt LC, et al. Medication compliance and disease exacerbation in patients with asthma: A retrospective study of managed care data. Annals of Allergy, Asthma, and Immunology. 2006(In press).

Bukstein DA, Murphy KR, Katz LM, McDermott L, Doyle JJ, Patel PA. Adherence with controller therapies and decreased asthma exacerbations in young children. Southwest Allergy Forum: Combined Meeting on Allergy, Asthma and Immunology; 2006 January Puerto Vallarta, Mexico; 2006.

Mannino DM, Shorr AF, Doyle JJ, Stern LS, Dolgitser M, Siegartel LR, et al. Prevalence of anemia in subjects with chronic obstructive pulmonary disease. American Thoracic Society; 2006 May; San Diego, California; 2006.

Marcus P, Oppenheimer EA, Patel PA, Katz LM, Doyle JJ. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Annals of Allergy, Asthema, & Immunology. 2006 May 2006;96:736-43.

Murphy KR, Bukstein DA, Katz LM, McDermott L, Stern LS, Patel PA. Earlier use of nebulized inhaled corticosteroids is associated with fewer asthma exacerbations in young children. Southwest Allergy Forum: Combined Meeting on Allergy, Asthma and Immunology; 2006 January; Puerto Vallarta, Mexico; 2006.

Murphy KR, Bukstein DA, Katz LM, McDermott L, Stern LS, Patel PA. Earlier use of nebulized inhaled corticosteroids is associated with fewer asthma exacerbations in young children. The Western Society of Allergy, Asthma, and Immunology; 2006 January; Lanai, Hawaii; 2006.

Shorr AF, Mannino DM, Doyle JJ, Stern LS, Dolgitser M, Siegartel LR, et al. Anemia in chronic obstructive pulmonary disease: Impact on resource utilization. American Thoracic Society; 2006 May San Diego, California; 2006.

Stern L, Berman J, Lumry W, Katz L, Wang L, Rosenblatt L, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Annals of Allergy, Asthma, & Immunology 2006;97:402-8.

Berman JM, Lumry WR, Stern LS, Katz LM, Wang L, Rosenblatt LC, et al. A retrospective analysis of medication compliance and disease exacerbation in patients with asthma. American College of Allergy, Asthma & Immunology 2005 Annual Meeting; 2005 November 6; Anaheim, California; 2005.

Bukstein DA, Murphy KR, Katz LM, McDermott L, Doyle JJ, Patel PA. Adherence with controller therapies and decreased asthma exacerbations in young children. American Thoracic Society International Conference; 2005 May; San Diego, California; 2005.

Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adult and elderly patients: An assessment of outcomes. The Western Society of Allergy, Asthma, and Immunology; 2005 January; Kauai, Hawaii; 2005.

Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adults and elderly patients: An assessment of outcomes. Southwest Allergy Forum: Combined Meeting on Allergy, Asthma and Immunology; 2005 January; Puerto Vallarta, Mexico; 2005.

Murphy KR, Bukstein DA, Katz LM, McDermott L, Stern LS, Patel PA. Use of nebulized inhaled corticosteroids is associated with fewer asthma exacerbations in young children. American Academy of Allergy, Asthma, and Immunology; 2005 March; San Antonio, Texas; 2005. p. Poster Presentation.

Niederman MS, Chalfin DB, Stern LS, Doyle JJ, Katz LM. Clinical and economic outcomes in patients treated with fluoroquinolone therapy in the intensive care unit. 40th ASHP Midyear Clinical Meeting and Exhibition; 2005 December Las Vegas, Nevada; 2005.

Stern LS, Doyle JJ, Katz LM, Dolgitser M. Use of intranasal amphotericin B in chronic rhinosinusitis patients: A survey of US otolaryngologists. American College of Allergy, Asthma & Immunology 2005 Annual Meeting; 2005 November 4-9; Anaheim, California; 2005.

Guo A, Doyle JJ, Stern LS, Chen Y, Etschmaier M. A Pre-Post Time in Motion Methodology to Examine Product Wastage Reduction: Pilot Results in Magnetic Resonance Contrast Media Pharmacy Bulk Pack The 2007 International Society for Pharmacoeconomics and Outcomes Research 2007 May 19-23, 2007; Arlington, VA 2007.

Krone FA. Bedeutung von Health Technology Assessment und Versorgungsforschung für Medizintechnologien im Gesundheitsmarkt., Berlin, Germany, June 19, 2007. (Workshop)

Krone FA. DGPharMed-Workshop - Health Technology Assessment: Welche Konsequenzen für die strategische und operative Ausrichtung von Unternehmen können gezogen werden? Würzburg, Germany, November 30, 2007. (Workshop)

Krone FA. Recent Healthcare Reforms in Germany and Implications for Outpatient Care. In: Health Economics 2007 Meeting, Informa Life Sciences, Brussels, Belgium, May 15 – 16, 2007.

Mueller E, Rosery H, Walzer S, Bergemann R. Is the German Institute for Quality and Efficiency in Health Care (IQWiG) prepared for competitive decision making ? In: European Society for Medical Decision Making, 10th Biennial European Meeting, Birmingham, UK, June 11-13, 2006.

Bergemann R. Charakteristika valider Health-Outcomes-Modelle. Gesundheitsökonomie & Qualitätsmanagement, 2005, Supplement 2, 10: S59–S63.

Kramer A, Daeschlein G, Kammerlander G, Andriessen A, Aspöck C, Bergemann R et al. Konsensusempfehlung. Geeignete Wirkstoffe zur Wundantiseptik 2. Wirkstoffe zur wiederholten Anwendung auf chronischen, schlecht heilenden bzw. empfindlichen Wunden. Procare, 2005 Nr. 1-2: 20